Previous studies have shown an equivalent pharmacokinetic profile between four-times-daily (4QD) and once-daily (QD) administration of intra-venous (IV) BU, without increased toxicity. We assess the impact of a switch in IV BU from a 4QD to a QD schedule, in terms of health-care organization, staff working conditions, quality of care dispensed and perceived patient comfort. Clinicians, nurses and pharmacists from nine allogeneic transplantation units in five European countries were interviewed face to face. Overall perception of QD versus 4QD BU was very positive. Both administration schemes were evaluated to be equally efficaciousZ. QD BU was perceived to be safer and more convenient. Clinicians and nurses perceived that patient comfort was improved, due to fewer complications associated with repeated infusions, and avoiding night infusions associated with stress, anxiety and decreased quality of sleep. Switching from 4QD to QD BU had a significant impact on health-care organization, with a better integration in the overall management and usual timelines in the pharmacies and transplantation units. Time spent to prepare and administer BU was significantly reduced, leading to potential financial savings that merit further assessment and would be of particular interest in the current economic climate.
INTRODUCTION
BU is commonly used as part of the conditioning regimen prior to allogeneic hematopoietic SCT (HSCT). The oral formulation of BU used to be associated with a high incidence of gastro-intestinal toxicity, such as emesis and mucositis. Moreover, absorption was erratic, leading to unpredictable bioavailability exposing the patient to either under-or over-exposure, respectively, associated with risks of inefficacy and toxicity. Lastly, gut absorption of BU may have contributed to sinusoid occlusion syndrome of the liver via a hepatic first-pass effect. The intra-venous (IV) formulation of BU reduced gastro-intestinal toxicity and decreased the intra-and inter-patient variability in bioavailability of the drug. 1, 2 Pharmacokinetic studies of IV BU have shown predictable linear kinetics, with less variability with the IV formulation reported than with the oral formulation. 3 IV BU has been associated with a decreased incidence of mucositis compared with the oral formulation, 1 as well as a lower incidence of hepatic sinusoid occlusion syndrome, sinusoid occlusion syndrome-related mortality and 100-day mortality. 4 Some studies have even showed lower rates of non-relapse mortality and relapse, as well as improved rates of overall and relapse-free survival with IV compared with oral BU. [5] [6] [7] Oral BU was developed in the 1950s for low-dose daily use in the treatment of chronic myeloid leukemia, in a form not adapted for high-dose conditioning regimens. As oral BU tablets were only available in 2-mg doses, in the transplantation setting, BU treatment was divided into four daily doses of 1 mg/kg each to improve patient compliance. When switching from an oral to an IV formulation, BU was initially administered four times daily (4QD) in doses of 0.8 mg/kg each, to mimic the usual schedule associated with the use of the oral formulation.
The availability of the IV BU formulation and its pharmacokinetic properties changed practical aspects of treatment: once-daily (QD) administration became possible and was attractive in terms of convenience. The conditioning strategy then changed radically with the development of reduced-intensity conditioning (RIC) regimens and the switch from CY to fludarabine. Subsequently, it was proposed that IV BU could be administered QD, in doses of 3.2 mg/kg/day, in RIC or myelo-ablative treatments. Several studies have shown comparable pharmacokinetic parameters of IV BU 4QD and QD schemes, with no significant differences in engraftment rates or post-transplantation complications. 8, 9 QD administration of IV BU was not associated with increased or unexpected toxicity. 9, 10 In addition to an equivalent pharmacokinetic profile, QD administration should have an impact on health-care organization, improving staff working conditions, quality of care dispensed and patient comfort. The aim of this study was to qualitatively assess and describe the impact of a switch in IV BU from a four-times-daily schedule to a QD schedule, as hypothesized above.
MATERIALS AND METHODS
The study was conducted in nine allogeneic HSCT units from October to December 2011 in France, Germany, Italy, Spain and Poland. Eligibility criteria were: centers performing 410 allogeneic HSCTs per year, having past experience of IV BU 4QD and having switched to the IV BU QD scheme at the time of interview. In each country, a list of eligible centers was created, and then randomly sorted. In these centers, the heads of hematology units were contacted respecting the order of the randomly sorted list until participation agreements were obtained from one or two centers per country. Clinicians, nurses and pharmacists were identified as key health-care professionals involved in the overall management of conditioning therapy. The heads of selected hematology departments who agreed to participate in the evaluation appointed a pharmacist in the hospital and a nurse in their department. Interviews were conducted face to face, separately, using a guide specifically developed and designed for each type of health-care professional, based on their area of expertise (that is, patient-related outcomes were asked of clinicians and nurses, whereas details on preparation of the drug were only part of the pharmacist and nurse questionnaires), as described in Table 1 . Each interview was B1 h long. The guides used were therefore strictly identical in all hospitals and included activity overview (patient flows), current and former protocols, key decision-making processes to switch from 4QD to the QD infusion scheme, drivers and barriers to switching from 4QD to the QD infusion scheme, perception of efficacy, safety and convenience of both schemes, impact on health-care organization in the department (time spent during preparation, administration and patient follow-up, medical resources used and so on), security of use for staff and impact for the patient in terms of comfort (Supplementary Files 1, 2 and 3) .
Clinicians, nurses and pharmacists were asked to rate their overall perception of QD BU compared with 4QD, in terms of efficacy, safety, convenience and perceived patient comfort using a visual scale, graduated from 0 to 10. A rating of five corresponded to equivalence between the QD and 4QD BU schemes; from 0 to 4 corresponded to the superiority of 4QD; and from 5 to 10 corresponded to the superiority of the QD BU scheme.
RESULTS
IV BU was used as part of a myelo-ablative or RIC regimen. QD BU was administered in a 3-h infusion of 3.2 mg/kg/day, whereas 4QD BU had previously been administered in four 2-h infusions of 0.8 mg/kg each.
Activity overview Conditioning protocols were homogeneous across the study countries. For the MAC regimen, seven centers (78%) previously used 4QD BU and eight centers (89%) currently use QD BU. Regarding the RIC regimen, five centers (56%) previously used 4QD BU and nine centers (100%) now use QD BU. One center used BU in RIC protocol only.
Switch from BU 4QD to the QD administration scheme: decision-making process In all cases, the decision to switch from the 4QD to the QD scheme was led by the hematologist, and pharmacists were also involved in the decision-making process in 15% of cases. Twenty-six percent of interviewees mentioned publications and clinical trials showing similar efficacy and toxicity for both schemes as the main drivers of this decision. All interviewees also mentioned the opportunity to achieve smoother organization in pharmacies and transplantation units. Few barriers to switching were spontaneously reported, except that QD BU is unlabeled.
Perception of BU QD administration scheme Overall perception of QD versus 4QD BU was very positive. Health-care professionals evaluated both administration schemes to be equally efficacious. QD BU was perceived to be safer and significantly more convenient (Table 2) . During interviews, health-care professionals mentioned that the QD scheme reduced the risks of errors and staff exposure, especially during preparation. All three types of health-care professionals had similar perceptions, with no major differences between countries.
Benefits for patients The BU QD scheme was perceived by health-care professionals to provide significant improvement of patient comfort (Table 2) . They mentioned during the interviews that the QD scheme was perceived to prevent complications for patients arising from repeated infusions (that is, infections), and to reduce nausea and vomiting, thereby fostering enteral feeding. In addition, it obviated the need for night infusions associated with stress, anxiety and decreased quality of sleep for patients.
Impact on health-care organization Switching from 4QD to QD BU had a major impact on health-care organization. The QD BU administration scheme is better Activity overview Actual and former administration schemes Key decision-maker(s) to switch from four-times-daily infusions to a QD infusion scheme Drivers and barriers to switch from four-times-daily infusions to a QD infusion scheme Perceived impact on patient comfort Impact on health-care organization in the department
Impact on time spent Preparation Administration Patient follow-up
Impact on safety during preparation and administration For paramedical staff/pharmacists For patients (avoided events and so on) Other impacts? (medical resources used and so on) Health-care organization and patient comfort with QD IV Bu A Xhaard et al integrated than 4QD BU in the overall management and usual timelines of other anti-cancer drugs in the pharmacy and HSCT units. In fact, BU was the only anti-cancer agent with a 4QD scheme that needed to be prepared twice a day to ensure drug stability, which was an issue for patients conditioned during weekends. For these patients, staff were required on weekends to prepare BU doses. For nurses, QD BU led to smoother timings for administering overall conditioning therapies. It also reduced the need to prepare BU in the ward at weekends in the absence of central pharmacy teams.
For each stage of processing (preparation, administration and follow-up), time spent by each health-care professional was estimated based on their declaration of average time spent. According to this analysis, the switch from 4QD IV BU infusions to the QD scheme led to savings of 42 h of nursing time and B1 h of pharmacy technician time per patient per day, amounting to time savings of 75 and 63%, respectively (Table 3) . QD BU was also mentioned as reducing the need for small medical devices (that is, tubings, bags and gloves) and concomitant drugs, such as antiemetics, parenteral nutrition and anxiolytics, leading to potential cost savings that merit further assessment (not analyzed in this study due to the wide disparity of labor costs in the survey countries).
DISCUSSION
In this study, administering IV BU QD was perceived to be safe, and to be equally as efficacious as the 4QD scheme. It was also perceived to be convenient and to improve patient comfort. Furthermore, it seemed to contribute to a greater optimization of human resources, which is of particular interest in the current economic climate.
As mentioned during interviews, the comparative ease of organizing the QD administration scheme might even allow IV BU to be administered QD on an outpatient basis, for both RIC and MAC conditioning regimens (as previously reported by Solomon et al. 11 and Subira et al.
12
). This practice might enable shorter hospital stays, contributing to an increase in the number of patients that can be treated in a single unit. From a patient perspective, an earlier discharge improves comfort and helps to preserve family life.
Slow annual growth in the number of teams performing HSCTs has been observed in Europe since 2005 (2% at most), despite much higher annual growth rates in both HSCT activity and allogeneic transplants. 13 Optimizing patient management with equivalent-size teams is likely to be a key concern in the near future. At the time of writing, economic conditions are not favorable in Europe: economic growth is, at best, virtually flat, increasing pre-existing state deficits and leading governments to Health-care organization and patient comfort with QD IV Bu A Xhaard et al implement drastic cost-containment measures to reduce or at least limit the growth of public expenditure, including health-care (health expenditure and financing: OECD Health Statistics). As a significant part of public health-care budgets, hospital expenses have already been affected by these cost-containment measures. Numerous reforms have taken place in the hospital setting over the last decade, streamlining patient management, optimizing health-care organization and strongly encouraging savings in hospital budgets. In this context, IV BU administered QD responds to the desire to optimize both the quality of hospital care and the allocation of scarce resources.
CONCLUSION
This study provides a perfect illustration of how therapeutic innovations can contribute to improving patient-related outcomes and the quality of health care dispensed, thereby leading to increased efficiency within health-care organizations. From a hospital perspective, switching to QD BU administration might enable better management of a greater number of patients receiving conditioning therapies prior to allogeneic HSCT, effectively coping with the higher demand in this area without increasing expenses. Future developments of this preliminary qualitative evaluation would include confirming these results with a prospective observational study measuring patient-related outcomes (such as patient comfort, which was assessed in our study by caregivers and should be confirmed by a quality of life assessment with an auto-administered questionnaire), time savings assessed with 'time and motion' measurements, and local costing and analyses of medical resources used.
